These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 27645281)
1. Sphingosine-1-phosphate restores endothelial barrier integrity in ovarian hyperstimulation syndrome. Scotti L; Di Pietro M; Pascuali N; Irusta G; I de Zúñiga ; Gomez Peña M; Pomilio C; Saravia F; Tesone M; Abramovich D; Parborell F Mol Hum Reprod; 2016 Dec; 22(12):852-866. PubMed ID: 27645281 [TBL] [Abstract][Full Text] [Related]
2. In vivo intrabursal administration of bioactive lipid sphingosine-1-phosphate enhances vascular integrity in a rat model of ovarian hyperstimulation syndrome. Di Pietro M; Pascuali N; Scotti L; Irusta G; Bas D; May M; Tesone M; Abramovich D; Parborell F Mol Hum Reprod; 2017 Jun; 23(6):417-427. PubMed ID: 28379469 [TBL] [Abstract][Full Text] [Related]
3. Platelet-derived growth factor B restores vascular barrier integrity and diminishes permeability in ovarian hyperstimulation syndrome. Pascuali N; Scotti L; Oubiña G; de Zúñiga I; Gomez Peña M; Pomilio C; Saravia F; Tesone M; Abramovich D; Parborell F Mol Hum Reprod; 2020 Aug; 26(8):585-600. PubMed ID: 32467982 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of angiopoietin-1 (ANGPT1) affects vascular integrity in ovarian hyperstimulation syndrome (OHSS). Scotti L; Abramovich D; Pascuali N; Durand LH; Irusta G; de Zúñiga I; Tesone M; Parborell F Reprod Fertil Dev; 2016 Apr; 28(6):690-9. PubMed ID: 25485810 [TBL] [Abstract][Full Text] [Related]
5. Ceramide-1-phosphate has protective properties against cyclophosphamide-induced ovarian damage in a mice model of premature ovarian failure. Pascuali N; Scotti L; Di Pietro M; Oubiña G; Bas D; May M; Gómez Muñoz A; Cuasnicú PS; Cohen DJ; Tesone M; Abramovich D; Parborell F Hum Reprod; 2018 May; 33(5):844-859. PubMed ID: 29534229 [TBL] [Abstract][Full Text] [Related]
6. Follicular fluid high-density lipoprotein-associated sphingosine 1-phosphate (S1P) promotes human granulosa lutein cell migration via S1P receptor type 3 and small G-protein RAC1. Becker S; von Otte S; Robenek H; Diedrich K; Nofer JR Biol Reprod; 2011 Mar; 84(3):604-12. PubMed ID: 20980685 [TBL] [Abstract][Full Text] [Related]
7. Alteration in angiogenic potential of granulosa-lutein cells and follicular fluid contributes to luteal defects in polycystic ovary syndrome. Patil K; Hinduja I; Mukherjee S Hum Reprod; 2021 Mar; 36(4):1052-1064. PubMed ID: 33377483 [TBL] [Abstract][Full Text] [Related]
8. Involvement of the ANGPTs/Tie-2 system in ovarian hyperstimulation syndrome (OHSS). Scotti L; Abramovich D; Pascuali N; de Zúñiga I; Oubiña A; Kopcow L; Lange S; Owen G; Tesone M; Parborell F Mol Cell Endocrinol; 2013 Jan; 365(2):223-30. PubMed ID: 23123737 [TBL] [Abstract][Full Text] [Related]
9. Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in an ovarian hyperstimulation syndrome (OHSS) animal model: implications for treatment of OHSS with dopamine receptor 2 agonists. Ferrero H; García-Pascual CM; Gaytán M; Morales C; Simón C; Gaytán F; Pellicer A; Gómez R Fertil Steril; 2014 Nov; 102(5):1468-1476.e1. PubMed ID: 25217874 [TBL] [Abstract][Full Text] [Related]
11. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Rizk B; Aboulghar M; Smitz J; Ron-El R Hum Reprod Update; 1997; 3(3):255-66. PubMed ID: 9322101 [TBL] [Abstract][Full Text] [Related]
12. Significance of pro-angiogenic estrogen metabolites in normal follicular development and follicular growth arrest in polycystic ovary syndrome. Henríquez S; Kohen P; Xu X; Villarroel C; Muñoz A; Godoy A; Strauss JF; Devoto L Hum Reprod; 2020 Jul; 35(7):1655-1665. PubMed ID: 32558920 [TBL] [Abstract][Full Text] [Related]
14. Sphingosine-1-phosphate prevents chemotherapy-induced human primordial follicle death. Li F; Turan V; Lierman S; Cuvelier C; De Sutter P; Oktay K Hum Reprod; 2014 Jan; 29(1):107-13. PubMed ID: 24221908 [TBL] [Abstract][Full Text] [Related]
15. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles. Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174 [TBL] [Abstract][Full Text] [Related]
16. The role of IL-6 trans-signaling in vascular leakage: implications for ovarian hyperstimulation syndrome in a murine model. Wei LH; Chou CH; Chen MW; Rose-John S; Kuo ML; Chen SU; Yang YS J Clin Endocrinol Metab; 2013 Mar; 98(3):E472-84. PubMed ID: 23348396 [TBL] [Abstract][Full Text] [Related]
17. Sphingosine 1-phosphate rapidly increases endothelial barrier function independently of VE-cadherin but requires cell spreading and Rho kinase. Xu M; Waters CL; Hu C; Wysolmerski RB; Vincent PA; Minnear FL Am J Physiol Cell Physiol; 2007 Oct; 293(4):C1309-18. PubMed ID: 17670896 [TBL] [Abstract][Full Text] [Related]
18. Sphingosine-1-phosphate prevents permeability increases via activation of endothelial sphingosine-1-phosphate receptor 1 in rat venules. Zhang G; Xu S; Qian Y; He P Am J Physiol Heart Circ Physiol; 2010 Nov; 299(5):H1494-504. PubMed ID: 20729401 [TBL] [Abstract][Full Text] [Related]
19. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome. Scotti L; Irusta G; Abramovich D; Tesone M; Parborell F Mol Cell Endocrinol; 2011 Mar; 335(2):116-25. PubMed ID: 21238536 [TBL] [Abstract][Full Text] [Related]
20. Follicular fluid levels of vascular endothelial growth factor. Are they predictive markers for ovarian hyperstimulation syndrome? Geva E; Amit A; Lessing JB; Lerner-Geva L; Daniel Y; Yovel I; Azem F; Barak V J Reprod Med; 1999 Feb; 44(2):91-6. PubMed ID: 10853438 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]